Therapeutics
100 VCs and 9 funds investing in Therapeutics
VCs investing in Therapeutics
Alex Morgan
Partner
Khosla Ventures
Check: No personal check range is published. Khosla's Seed Fund supports science and business-model experiments, historically often with roughly $1M–$2M according to a 2020 firm interview, while its Main Fund covers early through later stages. These are firm-level references, not Alex's authority.
Alex invests where computation, biology, and healthcare converge. His scientific and clinical background supports a systems view of biomarker discovery, therapeutics, diagnostics, personalized medicine, neurotechnology, connected devices, and AI-enabled care. He favors important health outcomes and technologies that can automate expensive or inconsistent processes, increase access, and create reproducible, lower-cost care—not science detached from delivery and economics.
Ian Metcalfe
Venture Partner, Therapeutics
NLC Health Ventures
Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.
Ian Metcalfe invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.
Sabine Kannegiesser
Partner
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Sabine Kannegiesser invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Rachelle Young
Investor Relations Director
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Rachelle Young as Investor Relations Director. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Elisa Camorani
Senior Associate ESG and Impact
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Elisa Camorani as Senior Associate ESG and Impact. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Cyril Lesser
Vice President Finance | Funds
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Cyril Lesser as Vice President Finance | Funds. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Benjamin Belot
Partner, Diagnostics
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Benjamin Belot as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Machteld Groeneveld
Chief Compliance Officer & Legal Affairs
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Machteld Groeneveld as Chief Compliance Officer & Legal Affairs. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Oskar Slotboom
Managing Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Oskar Slotboom as Managing Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Daniela Couto
General Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Daniela Couto as General Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Olga Ziessen
Manager Secretarial Services
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Olga Ziessen as Manager Secretarial Services. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Robbert van de Griendt
Head of Investor Relations
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Robbert van de Griendt as Head of Investor Relations. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Wouter Verhoeven
Venture Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Wouter Verhoeven as Venture Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Rianne Ellenbroek
Principal
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Rianne Ellenbroek as Principal. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
John J.P. Kastelein
Senior Advisor
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies John J.P. Kastelein as Senior Advisor. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Patricia Vonk
AML/KYC Manager
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Patricia Vonk as AML/KYC Manager. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Jennifer Fritzsche
Vice President Finance
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Jennifer Fritzsche as Vice President Finance. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Silva Dezelan
Head of Impact and ESG
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Silva Dezelan as Head of Impact and ESG. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Karen Chan
Associate
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Karen Chan as Associate. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Dragana Dragusin
Executive Assistant
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Dragana Dragusin as Executive Assistant. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Elena Ritsou
Venture Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Elena Ritsou as Venture Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Maureen Wouters
Paralegal
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Maureen Wouters as Paralegal. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Rob de Ree
Venture Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Rob de Ree as Venture Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Christina Takke
Managing Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Christina Takke as Managing Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Katja Rosenkranz
Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Katja Rosenkranz as Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Martin Solleveld
Finance Manager
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Martin Solleveld as Finance Manager. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Mathias Falcenberg
Venture Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Mathias Falcenberg as Venture Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Shelley Margetson
Managing Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Shelley Margetson as Managing Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Ward Capoen
Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Ward Capoen as Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Willem Broekaert
Managing Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Willem Broekaert as Managing Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Arnoud Dijkstra
Venture Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Arnoud Dijkstra as Venture Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Rémi Droller
Managing Partner, Biofund
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Rémi Droller as Managing Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Amanda Gett
Partner, Biofund
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Amanda Gett as Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Alain Horvais
Partner, Diagnostics
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Alain Horvais as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Thierry Laugel
Managing Partner, Biofund
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Thierry Laugel as Managing Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Peter Neubeck
Partner Germany, Biofund
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Peter Neubeck as Partner Germany, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Daniel Parera
Partner Germany, Growth Opportunities
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Daniel Parera as Partner Germany, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Philippe Peltier
Partner, Diagnostics
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Philippe Peltier as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Jean-François Rivassou
Partner, Growth Opportunities
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Jean-François Rivassou as Partner, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Hadrien Bouchez
Partner, Biofund
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Hadrien Bouchez as Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Laura Achach
Associate, Diagnostics
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Laura Achach as Associate, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Samantha Zennou
Associate, Diagnostics
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Samantha Zennou as Associate, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Florence de Coorebyter
Associate, Biofund
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Florence de Coorebyter as Associate, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Anna Tchorzewska
Associate, Biofund
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Anna Tchorzewska as Associate, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Maylis Deschamps
Associate, Growth Opportunities
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Maylis Deschamps as Associate, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Louise-Marie Rakotoarison
Analyst, Diagnostics
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Louise-Marie Rakotoarison as Analyst, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
Muriel Domine
Secretary General, Head of Compliance & Legal
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Muriel Domine as Secretary General, Head of Compliance & Legal. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Cyril Bedran
Financial Director
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Cyril Bedran as Financial Director. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Sonny Guilhem
Senior Financial Controller
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Sonny Guilhem as Senior Financial Controller. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Ornella Gomis
Financial Controller
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Ornella Gomis as Financial Controller. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Steffi Minga
Office Manager
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Steffi Minga as Office Manager. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Fatima Boubnad
Management Assistant
Kurma Partners
Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Fatima Boubnad as Management Assistant. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Gaston Matthyssens, PhD
Managing Partner
Vesalius Biocapital
Check: Vesalius Biocapital does not publish a standard current check-size range on its official site.
Gaston Matthyssens, PhD invests or supports investments through Vesalius Biocapital's published strategy: Build a concentrated European life-sciences portfolio across therapeutics, diagnostics, medical devices and digital health with active strategic support.
Alain Parthoens
Managing Partner
Vesalius Biocapital
Check: Vesalius Biocapital does not publish a standard current check-size range on its official site.
Alain Parthoens invests or supports investments through Vesalius Biocapital's published strategy: Build a concentrated European life-sciences portfolio across therapeutics, diagnostics, medical devices and digital health with active strategic support.
Christian Schneider, PhD
Managing Partner
Vesalius Biocapital
Check: Vesalius Biocapital does not publish a standard current check-size range on its official site.
Christian Schneider, PhD invests or supports investments through Vesalius Biocapital's published strategy: Build a concentrated European life-sciences portfolio across therapeutics, diagnostics, medical devices and digital health with active strategic support.
Stephane Verdood
Managing Partner
Vesalius Biocapital
Check: Vesalius Biocapital does not publish a standard current check-size range on its official site.
Stephane Verdood invests or supports investments through Vesalius Biocapital's published strategy: Build a concentrated European life-sciences portfolio across therapeutics, diagnostics, medical devices and digital health with active strategic support.
Guy Geldhof
Partner
Vesalius Biocapital
Check: Vesalius Biocapital does not publish a standard current check-size range on its official site.
Guy Geldhof invests or supports investments through Vesalius Biocapital's published strategy: Build a concentrated European life-sciences portfolio across therapeutics, diagnostics, medical devices and digital health with active strategic support.
Dr. Rainer Strohmenger
Managing Partner
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Rainer Strohmenger invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Dr. Johannes Fischer
Managing Partner
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Johannes Fischer invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Dr. Varun Gupta
Partner
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Varun Gupta invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Harald Keller
Managing Partner, CFO
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Harald Keller is listed in a Managing Partner, CFO capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Ernst Mannheimer
Managing Partner, Legal Counsel
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Ernst Mannheimer is listed in a Managing Partner, Legal Counsel capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Ileana Lindeman
Venture Partner, Orthopedics, Spine & Surgery
NLC Health Ventures
Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.
Ileana Lindeman invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.
Dr. Lisa Gartenmann
Manager
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Lisa Gartenmann invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Dr. Robert Buschauer
Associate
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Robert Buschauer invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Karina Schuster
Office Manager
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Karina Schuster is listed in a Office Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Ulrike Spring
Sustainability Manager
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Ulrike Spring is listed in a Sustainability Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Cornelia Huber
Finance Manager
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Cornelia Huber is listed in a Finance Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Karin Juen
Finance Manager
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Karin Juen is listed in a Finance Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Anja Weibel
Finance Manager
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Anja Weibel is listed in a Finance Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Olena Ionkina
Finance Manager
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Olena Ionkina is listed in a Finance Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Doris Gowik
Project Manager
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Doris Gowik invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Dr. Regina Hodits
Venture Advisor
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Regina Hodits is listed in a Venture Advisor capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Prof. Dr. Erich Schlick
Venture Partner
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Prof. Dr. Erich Schlick invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Dr. Ulrich Granzer
Venture Partner
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Ulrich Granzer invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Dr. Mel Spigelman
Venture Partner
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Mel Spigelman invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Dr. Wolfgang Baiker
Venture Partner
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Wolfgang Baiker invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Stuart Essig, Ph.D.
Venture Partner
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Stuart Essig, Ph.D. invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Dr. Bo Jesper Hansen
Venture Partner
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Bo Jesper Hansen invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Dr. Peter Hirth
Venture Partner
Wellington Partners
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Peter Hirth invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Alain Parthoens
Chief Executive Officer
Newton Biocapital
Check: Newton Biocapital does not publish a standard current check-size range on its official site.
Alain Parthoens is listed in a Chief Executive Officer capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Sadashi Suzuki
Japan Representative
Newton Biocapital
Check: Newton Biocapital does not publish a standard current check-size range on its official site.
Sadashi Suzuki is listed in a Japan Representative capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Guy Heynen
Chief Medical and Regulatory Officer
Newton Biocapital
Check: Newton Biocapital does not publish a standard current check-size range on its official site.
Guy Heynen is listed in a Chief Medical and Regulatory Officer capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Michihiko Wada
Chief Regulatory and Development Officer
Newton Biocapital
Check: Newton Biocapital does not publish a standard current check-size range on its official site.
Michihiko Wada is listed in a Chief Regulatory and Development Officer capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Danny Gonnissen
Chief Operating Officer
Newton Biocapital
Check: Newton Biocapital does not publish a standard current check-size range on its official site.
Danny Gonnissen is listed in a Chief Operating Officer capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Pierre Detrixhe
Venture Director
Newton Biocapital
Check: Newton Biocapital does not publish a standard current check-size range on its official site.
Pierre Detrixhe invests or supports investments through Newton Biocapital's published strategy: Invest in private life-sciences companies in Europe and Japan whose products address important unmet medical needs.
Tomoko Asaoka
Partner
Newton Biocapital
Check: Newton Biocapital does not publish a standard current check-size range on its official site.
Tomoko Asaoka invests or supports investments through Newton Biocapital's published strategy: Invest in private life-sciences companies in Europe and Japan whose products address important unmet medical needs.
Dario Padovani
Chief Financial Officer
Newton Biocapital
Check: Newton Biocapital does not publish a standard current check-size range on its official site.
Dario Padovani is listed in a Chief Financial Officer capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Daisuke Morishita
Venture Partner
Newton Biocapital
Check: Newton Biocapital does not publish a standard current check-size range on its official site.
Daisuke Morishita invests or supports investments through Newton Biocapital's published strategy: Invest in private life-sciences companies in Europe and Japan whose products address important unmet medical needs.
Toko Senna
Assistant to the CEO / Office Manager
Newton Biocapital
Check: Newton Biocapital does not publish a standard current check-size range on its official site.
Toko Senna is listed in a Assistant to the CEO / Office Manager capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Ajit Shetty
Chairman of the Board of NBC I and NBC II
Newton Biocapital
Check: Newton Biocapital does not publish a standard current check-size range on its official site.
Ajit Shetty is listed in a Chairman of the Board of NBC I and NBC II capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Dirk Boogmans
Vice-Chairman and Chairman of the Audit Committee of NBC I and NBC II
Newton Biocapital
Check: Newton Biocapital does not publish a standard current check-size range on its official site.
Dirk Boogmans is listed in a Vice-Chairman and Chairman of the Audit Committee of NBC I and NBC II capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Jean Combalbert
Independent Director
Newton Biocapital
Check: Newton Biocapital does not publish a standard current check-size range on its official site.
Jean Combalbert is listed in a Independent Director capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Jean-Claude Deschamps
Chairman Emeritus and Advisor to the Board of NBC I and NBC II
Newton Biocapital
Check: Newton Biocapital does not publish a standard current check-size range on its official site.
Jean-Claude Deschamps is listed in a Chairman Emeritus and Advisor to the Board of NBC I and NBC II capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Goro Takeda
Founder
Newton Biocapital
Check: Newton Biocapital does not publish a standard current check-size range on its official site.
Goro Takeda is listed in a Founder capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Bert-Arjan Millenaar
Founder & CEO
NLC Health Ventures
Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.
Bert-Arjan Millenaar is listed in a Founder & CEO capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Ruben Mikkers
CFO
NLC Health Ventures
Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.
Ruben Mikkers is listed in a CFO capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Amalia Stenberg
Head of Legal, Company Secretary
NLC Health Ventures
Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.
Amalia Stenberg is listed in a Head of Legal, Company Secretary capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Emke Bus
Head of Investor Relations & Business Development
NLC Health Ventures
Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.
Emke Bus is listed in a Head of Investor Relations & Business Development capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Nia Emami-Shahri, PhD
Entrepreneur in Residence
NLC Health Ventures
Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.
Nia Emami-Shahri, PhD is listed in a Entrepreneur in Residence capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Funds focused on Therapeutics
Forbion
Naarden, Netherlands
Gilde Healthcare
Utrecht, Netherlands
NLC Health Ventures
Amsterdam, Netherlands
Wellington Partners
Munich, Germany
Kurma Partners
Paris, France / Munich, Germany
BioGeneration Ventures
Naarden, Netherlands
Newton Biocapital
Brussels, Belgium and Tokyo, Japan
V-Bio Ventures
Ghent, Belgium
Vesalius Biocapital
Luxembourg